

Appointment of Dr Dimitris Voliotis as Chief Medical Officer

Sydney, Australia – 20 August 2024 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Dimitris Voliotis as Chief Medical Officer.

Dr Voliotis has built almost 20 years of pharma and biotechnology expertise across the US and Europe, with an emphasis on the radiopharmaceutical sector, backed by 12 years of academic preclinical and clinical research.

His industry experience includes global drug development roles in large and medium-sized pharmaceutical companies through to those at start-up phase.

Dr Voliotis has designed and executed multiple registrational trials in numerous oncology indications, multiple INDs (investigational new drug applications), preclinical through to first in human trials including Phase 1 through 4. Consequently, Dr Voliotis has overseen numerous regulatory submissions which have resulted in approvals for four drugs in eight different oncology indications.

Based in New Jersey, USA, Dr Voliotis was most recently Senior Vice President, Head of Clinical Development of radiopharmaceutical business Convergent Therapeutics, while prior to this holding the same role with oncology company Zentalis Pharmaceuticals (NASDAQ: ZNTL). He also previously spent almost 13 years in a range of development roles with major German multinational pharma company Bayer AG as well as at Japanese company Eisai Inc.

Dr Voliotis has also recently acted as a Consultant in Oncology Drug Development with Magnesia Partners Consulting LLC, advising across clinical development and regulatory strategy.

Dr Voliotis is a graduate of the University of Cologne Medical School, where he also completed his doctoral thesis in cellular biology. He served as a Senior Consultant in Oncology and Head, Laboratory for Diagnostic Hematology and Immunohematology. Dr Voliotis is board certified in Internal Medicine, Medical Oncology and Hematology.

Riccardo Canevari, CEO & Managing Director of Radiopharm, commented: “We’re very pleased to attract an experienced and knowledgeable leader of Dr Voliotis experience to the role of CMO at RAD. We are confident his hands-on approach, strategic thinking and interpersonal skills will be of significant benefit to the company and the development of our technologies.”

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. Learn more at Radiopharmtheranostics.com.

**ASX ANNOUNCEMENT
20 AUGUST 2024**



Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>
Twitter – <https://twitter.com/TeamRadiopharm>
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>
InvestorHub – <https://investorhub.radiopharmtheranostics.com/>